Anti-Inflammatory Biologics Market Size, Share, and Trends 2024 to 2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Anti-Inflammatory Biologics Market 

5.1. COVID-19 Landscape: Anti-Inflammatory Biologics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Anti-Inflammatory Biologics Market, By Drug Class

8.1. Anti-Inflammatory Biologics Market, by Drug Class, 2024-2033

8.1.1. Anti-tumor Necrosis Factor (TNF)

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Interleukins Antagonists

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Janus Kinase (JAK) Inhibitor

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. Others

8.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Anti-Inflammatory Biologics Market, By Application

9.1. Anti-Inflammatory Biologics Market, by Application, 2024-2033

9.1.1. Rheumatoid Arthritis

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Psoriasis

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Others

9.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Anti-Inflammatory Biologics Market, By Route of Administration 

10.1. Anti-Inflammatory Biologics Market, by Route of Administration, 2024-2033

10.1.1. Oral

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Injection

10.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Anti-Inflammatory Biologics Market, By Distributional Channel 

11.1. Anti-Inflammatory Biologics Market, by Distributional Channel, 2024-2033

11.1.1. Hospital Pharmacy

11.1.1.1. Market Revenue and Forecast (2021-2033)

11.1.2. Retail Pharmacy

11.1.2.1. Market Revenue and Forecast (2021-2033)

11.1.3. Online Pharmacy

11.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 12. Global Anti-Inflammatory Biologics Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Drug Class (2021-2033)

12.1.2. Market Revenue and Forecast, by Application (2021-2033)

12.1.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

12.1.4. Market Revenue and Forecast, by Distributional Channel (2021-2033)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)

12.1.5.2. Market Revenue and Forecast, by Application (2021-2033)

12.1.5.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

12.1.5.4. Market Revenue and Forecast, by Distributional Channel (2021-2033)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)

12.1.6.2. Market Revenue and Forecast, by Application (2021-2033)

12.1.6.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

12.1.6.4. Market Revenue and Forecast, by Distributional Channel (2021-2033)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Drug Class (2021-2033)

12.2.2. Market Revenue and Forecast, by Application (2021-2033)

12.2.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

12.2.4. Market Revenue and Forecast, by Distributional Channel (2021-2033)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)

12.2.5.2. Market Revenue and Forecast, by Application (2021-2033)

12.2.5.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

12.2.5.4. Market Revenue and Forecast, by Distributional Channel (2021-2033)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)

12.2.6.2. Market Revenue and Forecast, by Application (2021-2033)

12.2.6.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

12.2.6.4. Market Revenue and Forecast, by Distributional Channel (2021-2033)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Drug Class (2021-2033)

12.2.7.2. Market Revenue and Forecast, by Application (2021-2033)

12.2.7.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

12.2.7.4. Market Revenue and Forecast, by Distributional Channel (2021-2033)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Drug Class (2021-2033)

12.2.8.2. Market Revenue and Forecast, by Application (2021-2033)

12.2.8.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

12.2.8.4. Market Revenue and Forecast, by Distributional Channel (2021-2033)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Drug Class (2021-2033)

12.3.2. Market Revenue and Forecast, by Application (2021-2033)

12.3.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

12.3.4. Market Revenue and Forecast, by Distributional Channel (2021-2033)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)

12.3.5.2. Market Revenue and Forecast, by Application (2021-2033)

12.3.5.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

12.3.5.4. Market Revenue and Forecast, by Distributional Channel (2021-2033)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)

12.3.6.2. Market Revenue and Forecast, by Application (2021-2033)

12.3.6.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

12.3.6.4. Market Revenue and Forecast, by Distributional Channel (2021-2033)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Drug Class (2021-2033)

12.3.7.2. Market Revenue and Forecast, by Application (2021-2033)

12.3.7.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

12.3.7.4. Market Revenue and Forecast, by Distributional Channel (2021-2033)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Drug Class (2021-2033)

12.3.8.2. Market Revenue and Forecast, by Application (2021-2033)

12.3.8.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

12.3.8.4. Market Revenue and Forecast, by Distributional Channel (2021-2033)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)

12.4.2. Market Revenue and Forecast, by Application (2021-2033)

12.4.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

12.4.4. Market Revenue and Forecast, by Distributional Channel (2021-2033)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)

12.4.5.2. Market Revenue and Forecast, by Application (2021-2033)

12.4.5.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

12.4.5.4. Market Revenue and Forecast, by Distributional Channel (2021-2033)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)

12.4.6.2. Market Revenue and Forecast, by Application (2021-2033)

12.4.6.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

12.4.6.4. Market Revenue and Forecast, by Distributional Channel (2021-2033)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Drug Class (2021-2033)

12.4.7.2. Market Revenue and Forecast, by Application (2021-2033)

12.4.7.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

12.4.7.4. Market Revenue and Forecast, by Distributional Channel (2021-2033)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Drug Class (2021-2033)

12.4.8.2. Market Revenue and Forecast, by Application (2021-2033)

12.4.8.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

12.4.8.4. Market Revenue and Forecast, by Distributional Channel (2021-2033)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)

12.5.2. Market Revenue and Forecast, by Application (2021-2033)

12.5.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

12.5.4. Market Revenue and Forecast, by Distributional Channel (2021-2033)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)

12.5.5.2. Market Revenue and Forecast, by Application (2021-2033)

12.5.5.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

12.5.5.4. Market Revenue and Forecast, by Distributional Channel (2021-2033)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)

12.5.6.2. Market Revenue and Forecast, by Application (2021-2033)

12.5.6.3. Market Revenue and Forecast, by Route of Administration (2021-2033)

12.5.6.4. Market Revenue and Forecast, by Distributional Channel (2021-2033)

Chapter 13. Company Profiles

13.1. Amgen Inc

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Novartis AG

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. AstraZeneca PLC.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Johnson & Johnson

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. PFIZER INC.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. GlaxoSmithKline plc

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. F.Hoffmann-La Roche AG

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Merck & Co., Inc.

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Eli Lily and Company

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms